Handelsman Yehuda
Metabolic Institute of America, Tarzana, CA 91356, USA.
Postgrad Med. 2009 May;121(3 Suppl 1):19-24. doi: 10.3810/pgm.2009.05.suppl53.289.
Colesevelam hydrochloride (HCl) was approved in January 2008 as an adjunct therapy for improving glycemic control in patients with type 2 diabetes mellitus (T2DM). Colesevelam HCl is a bile acid sequestrant that has been shown to significantly improve both glycemic control and the lipid profile in patients with T2DM when added to metformin-, sulfonylurea-, or insulin-based therapy. In addition, colesevelam HCl may be useful for reducing glucose and low-density lipoprotein cholesterol levels in patients with prediabetes (defined as fasting plasma glucose levels of 100-125 mg/dL or 2-hour poststimulation glucose levels of 140-199 mg/dL), who have an increased cardiovascular risk. As colesevelam HCl is a unique agent-with both significant glycemic and lipid benefits-it has the potential to play an important role in the management of T2DM. This article reviews the place of colesevelam HCl in therapy (both for T2DM and prediabetes), the benefits of early, intensive treatment of T2DM, and the importance of safe glycemic control later in the disease process.
盐酸考来维仑于2008年1月被批准作为辅助疗法，用于改善2型糖尿病（T2DM）患者的血糖控制。盐酸考来维仑是一种胆汁酸螯合剂，已证明在二甲双胍、磺脲类或胰岛素治疗基础上加用盐酸考来维仑，可显著改善T2DM患者的血糖控制和血脂水平。此外，盐酸考来维仑可能有助于降低糖尿病前期患者（定义为空腹血糖水平为100 - 125mg/dL或刺激后2小时血糖水平为140 - 199mg/dL）的血糖和低密度脂蛋白胆固醇水平，这些患者心血管风险增加。由于盐酸考来维仑是一种独特的药物，具有显著的血糖和血脂益处，它有可能在T2DM的管理中发挥重要作用。本文综述了盐酸考来维仑在治疗（包括T2DM和糖尿病前期）中的地位、T2DM早期强化治疗的益处以及疾病后期安全血糖控制的重要性。
